About
Profile
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple ret
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
OCGN
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Ocugen launches $20 million direct offering of common stock, warrants
- Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials
- Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.37M beats by $1.02M
- Ocugen Q2 2025 Earnings Preview
- Ocugen gets FDA clearance to begin mid-stage study of OCU410ST
- Ocugen signs license deal with Korean company for gene therapy
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
- Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment
- Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track
- Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.48M
- Ocugen Q1 2025 Earnings Preview
- Ocugen GAAP EPS of -$0.05 in-line, revenue of $0.76M beats by $0.46M
- Ocugen Q4 2024 Earnings Preview
- Ocugen aligns with FDA on confirmatory study for OCU410ST
- Ocugen gets positive EU opinion for ATMP classification for OCU400
- Ocugen files to sell 57.54M shares of common stock for holders
- Ocugen reports positive data for OCU400, OCU410
- Ocugen reports Q3 results
- Ocugen Q3 2024 Earnings Preview
| Date | Price | Open | High | Low | Vol | Change | ER | |||
|---|---|---|---|---|---|---|---|---|---|---|
| May 26, 2023 | 0.46 | 0.45 |
0.47
|
0.44
|
12.2M | 2.22% | ||||
| May 25, 2023 | 0.45 | 0.48 |
0.49
|
0.45
|
14.9M | -4.26% | ||||
| May 24, 2023 | 0.47 | 0.55 |
0.57
|
0.44
|
44.9M | -34.72% | ||||
| May 23, 2023 | 0.72 | 0.72 |
0.78
|
0.72
|
9.0M | 0% | ||||
| May 22, 2023 | 0.72 | 0.67 |
0.73
|
0.66
|
8.5M | 7.46% | ||||
| May 19, 2023 | 0.67 | 0.66 |
0.68
|
0.65
|
6.8M | 1.52% | ||||
| May 18, 2023 | 0.66 | 0.7 |
0.7
|
0.63
|
10.4M | -4.35% | ||||
| May 17, 2023 | 0.69 | 0.7 |
0.7
|
0.68
|
2.4M | 0% | ||||
| May 16, 2023 | 0.69 | 0.7 |
0.75
|
0.68
|
5.9M | -5.48% | ||||
| May 15, 2023 | 0.73 | 0.68 |
0.74
|
0.67
|
6.6M | 7.35% | ||||
| May 12, 2023 | 0.68 | 0.71 |
0.71
|
0.66
|
5.3M | -2.86% | ||||
| May 11, 2023 | 0.7 | 0.75 |
0.76
|
0.7
|
5.8M | -6.67% | ||||
| May 10, 2023 | 0.75 | 0.74 |
0.77
|
0.73
|
5.4M | 2.74% | ||||
| May 9, 2023 | 0.73 | 0.72 |
0.74
|
0.7
|
5.2M | 1.39% | ||||
| May 8, 2023 | 0.72 | 0.71 |
0.75
|
0.71
|
7.9M | 2.86% | ||||
| May 5, 2023 | 0.7 | 0.72 |
0.72
|
0.69
|
5.1M | 1.45% | ||||
| May 4, 2023 | 0.69 | 0.7 |
0.72
|
0.68
|
4.2M | -1.43% | ||||
| May 3, 2023 | 0.7 | 0.68 |
0.72
|
0.68
|
5.4M | 2.94% | ||||
| May 2, 2023 | 0.68 | 0.7 |
0.71
|
0.67
|
5.5M | -2.86% | ||||
| May 1, 2023 | 0.7 | 0.72 |
0.72
|
0.7
|
3.6M | -1.41% | ||||
| Apr 28, 2023 | 0.71 | 0.71 |
0.73
|
0.69
|
5.4M | 0% | ||||
| Apr 27, 2023 | 0.71 | 0.73 |
0.75
|
0.7
|
5.1M | -1.39% | ||||
| Apr 26, 2023 | 0.72 | 0.71 |
0.73
|
0.68
|
9.6M | 1.41% | ||||
| Apr 25, 2023 | 0.71 | 0.72 |
0.74
|
0.7
|
8.6M | -1.39% | ||||
| Apr 24, 2023 | 0.72 | 0.8 |
0.81
|
0.7
|
7.5M | -8.86% | ||||
| Apr 21, 2023 | 0.79 | 0.82 |
0.84
|
0.78
|
4.0M | -3.66% | ||||
| Apr 20, 2023 | 0.82 | 0.86 |
0.87
|
0.81
|
3.7M | -5.75% | ||||
| Apr 19, 2023 | 0.87 | 0.85 |
0.89
|
0.83
|
3.8M | 0% | ||||
| Apr 18, 2023 | 0.87 | 0.83 |
0.89
|
0.81
|
6.3M | 6.10% | ||||
| Apr 17, 2023 | 0.82 | 0.81 |
0.82
|
0.79
|
2.1M | 2.50% | ||||
| Apr 14, 2023 | 0.8 | 0.87 |
0.87
|
0.79
|
4.9M | -5.88% | ||||
| Apr 13, 2023 | 0.85 | 0.81 |
0.87
|
0.8
|
4.0M | 7.59% | ||||
| Apr 12, 2023 | 0.79 | 0.82 |
0.83
|
0.78
|
2.5M | -2.47% | ||||
| Apr 11, 2023 | 0.81 | 0.76 |
0.81
|
0.75
|
5.9M | 8% | ||||
| Apr 10, 2023 | 0.75 | 0.79 |
0.8
|
0.75
|
3.8M | -3.85% | ||||
| Apr 6, 2023 | 0.78 | 0.78 |
0.81
|
0.75
|
2.6M | 2.63% | ||||
| Apr 5, 2023 | 0.76 | 0.82 |
0.82
|
0.76
|
3.5M | -6.17% | ||||
| Apr 4, 2023 | 0.81 | 0.87 |
0.87
|
0.81
|
3.5M | -5.81% | ||||
| Apr 3, 2023 | 0.86 | 0.86 |
0.89
|
0.86
|
2.7M | 1.18% | ||||
| Mar 31, 2023 | 0.85 | 0.84 |
0.87
|
0.82
|
3.1M | 3.66% | ||||
| Mar 30, 2023 | 0.82 | 0.89 |
0.89
|
0.82
|
4.3M | -6.82% | ||||
| Mar 29, 2023 | 0.88 | 0.85 |
0.9
|
0.84
|
4.3M | 6.02% | ||||
| Mar 28, 2023 | 0.83 | 0.9 |
0.91
|
0.83
|
4.5M | -6.74% | ||||
| Mar 27, 2023 | 0.89 | 0.94 |
0.94
|
0.88
|
4.6M | -3.26% | ||||
| Mar 24, 2023 | 0.92 | 0.87 |
0.94
|
0.87
|
4.1M | 4.55% | ||||
| Mar 23, 2023 | 0.88 | 0.92 |
0.94
|
0.86
|
5.1M | -3.3% | ||||
| Mar 22, 2023 | 0.91 | 0.97 |
0.97
|
0.89
|
7.8M | -4.21% | ||||
| Mar 21, 2023 | 0.95 | 0.94 |
0.96
|
0.93
|
7.4M | 0% | ||||
| Mar 20, 2023 | 0.95 | 0.97 |
0.97
|
0.91
|
9.9M | -2.06% | ||||
| Mar 17, 2023 | 0.97 | 1 |
1.05
|
0.95
|
37.5M | -3.96% | ||||
| Mar 16, 2023 | 1.01 | 0.91 |
1.02
|
0.9
|
11.3M | 9.78% | ||||
| Mar 15, 2023 | 0.92 | 0.92 |
0.94
|
0.9
|
10.6M | -2.13% | ||||
| Mar 14, 2023 | 0.94 | 0.91 |
0.97
|
0.91
|
6.3M | 3.30% | ||||
| Mar 13, 2023 | 0.91 | 0.89 |
0.96
|
0.89
|
6.0M | -1.09% | ||||
| Mar 10, 2023 | 0.92 | 0.89 |
0.94
|
0.85
|
10.0M | 3.37% | ||||
| Mar 9, 2023 | 0.89 | 0.95 |
0.96
|
0.88
|
9.0M | -5.32% | ||||
| Mar 8, 2023 | 0.94 | 0.97 |
0.99
|
0.91
|
11.7M | -3.09% | ||||
| Mar 7, 2023 | 0.97 | 0.98 |
1.01
|
0.96
|
6.8M | -1.02% | ||||
| Mar 6, 2023 | 0.98 | 1.02 |
1.04
|
0.97
|
5.8M | -5.77% | ||||
| Mar 3, 2023 | 1.04 | 1.01 |
1.04
|
1
|
4.8M | 0% | ||||